These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29259533)

  • 61. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
    Nagai S; Ozawa K
    Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of guidelines for biological ancillary materials used for the manufacture of gene and cellular therapy products in Asia.
    Tanaka T; Yoshimura K; Chang R; Choi B; Gai Y; Gupta PK; Kolkundkar U; Lee SM; Lee S; Liao W; Zhao X; Takakura K
    Cytotherapy; 2023 Feb; 25(2):220-228. PubMed ID: 36274006
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
    Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
    Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quality Requirements for Medicinal Cannabis and Respective Products in the European Union - Status Quo.
    Veit M
    Planta Med; 2023 Jul; 89(8):808-823. PubMed ID: 35338476
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Factors That Facilitate Regulatory Approval for Drug-Device Combination Products in the European Union and United States of America: A Mixed Method Study of Industry Views.
    Masterson F
    Ther Innov Regul Sci; 2018 Jul; 52(4):489-498. PubMed ID: 29714544
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The European hospital exemption clause-new option for gene therapy?
    Buchholz CJ; Sanzenbacher R; Schüle S
    Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 69. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
    Damerval M; Fagnoni-Legat C; Louvrier A; Fischer S; Limat S; Clairet AL; Nerich V; Madelaine I; Kroemer M
    Front Med (Lausanne); 2021; 8():713047. PubMed ID: 34926483
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Guidance for pediatric use in prescription information for novel medicinal products in the EU and the US.
    Christiansen H; De Bruin ML; Frokjaer S; Hallgreen CE
    PLoS One; 2022; 17(4):e0266353. PubMed ID: 35377911
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Creating conditions for the success of the French industrial advanced therapy sector.
    Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F
    Therapie; 2015; 70(1):69-94. PubMed ID: 25747840
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
    Salmon F; Grosios K; Petry H
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports.
    Kurauchi R; Kasai H; Ito T
    Front Bioeng Biotechnol; 2020; 8():606606. PubMed ID: 33425872
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
    Dwenger A; Strassburger J; Schwerdtfeger W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regulatory advice and drug development--a case study in negotiating with regulators.
    Seldrup J
    Stat Med; 2011 Jun; 30(13):1628-35. PubMed ID: 21365671
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
    Reichert JM; Healy EM
    Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
    White M; Whittaker R; Gándara C; Stoll EA
    Hum Gene Ther Methods; 2017 Aug; 28(4):163-176. PubMed ID: 28817344
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.